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Abstract: High TIMP1 expression is associated with poor prognosis in melanoma, where it can
bind to CD63 and β1 integrin, inducing PI3-kinase pathway and cell survival. Phosphatidylinositol
(3,4,5)-trisphosphate (PIP3), generated under phosphatidylinositol-3-kinase (PI3K) activation, enables
the recruitment and activation of protein kinase B (PKB/AKT) and phosphoinositide-dependent
kinase 1 (PDK1) at the membrane, resulting in the phosphorylation of a host of other proteins.
Using a melanoma progression model, we evaluated the impact of Timp1 and AKT silencing,
as well as PI3K, PDK1, and protein kinase C (PKC) inhibitors on aggressiveness characteristics.
Timp1 downregulation resulted in decreased anoikis resistance, clonogenicity, dacarbazine resistance,
and in vivo tumor growth and lung colonization. In metastatic cells, pAKTThr308 is highly expressed,
contributing to anoikis resistance. We showed that PDK1Ser241 and PKCβIISer660 are activated by
Timp1 in different stages of melanoma progression, contributing to colony formation and anoikis
resistance. Moreover, simultaneous inhibition of Timp1 and AKT in metastatic cells resulted in
more effective anoikis inhibition. Our findings demonstrate that Timp1 promotes cell survival with
the participation of PDK1 and PKC in melanoma. In addition, Timp1 and AKT act synergistically
to confer anoikis resistance in advanced tumor stages. This study brings new insights about the
mechanisms by which Timp1 promotes cell survival in melanoma, and points to novel perspectives
for therapeutic approaches.
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1. Introduction
Cutaneous melanoma is a melanocytic tumor whose incidence and mortality are on the rise
worldwide. Although melanoma accounts for only 4% of all skin cancers, its mortality rate corresponds
to 74% of those related to skin cancer in general [1]. The overall incidence is 160,000 cases,
with 48,000 deaths per year [1].
MAPK signaling pathway (mitogen activated protein kinase), including the cascade of proteins
NRAS, BRAF, MEK1/2, and ERK1/2, is one of most-studied signaling pathways in melanoma.
This path is considered the main route changed in melanoma and is involved in cell survival,
proliferation, and migration, and is related to both development and melanoma progression [2]. So far,
the best characterized effectors of RAS proteins are RAF kinase and phosphatidylinositol-3-kinase
(PI3K) [3].
Cancers 2017, 9, 37; doi:10.3390/cancers9040037 www.mdpi.com/journal/cancers
Cancers 2017, 9, 37 2 of 15
The phosphatidylinositol-3-kinase (PI3K) pathway is one of the most important pathways in
cancer metabolism and growth. One of the key effector proteins in this pathway is known as PKB
(protein kinase B) or AKT, which has three isoforms (AKT1, AKT2, and AKT3), with AKT3 being found
frequently activated in melanomas [3]. By phosphorylation of several intracellular substrates, AKT can
modulate various biological processes, such as survival, cell cycle progression, growth, and cell
metabolism. AKT activation is initiated when the translocated AKT is phosphorylated at threonine 308
(Thr308) by phosphoinositide-dependent kinase 1 (PDK1) [4]. However, the complete activation occurs
only when serine 473 is phosphorylated by the mTORC2 complex [5]. Phosphoinositide-dependent
kinase 1 (PDK1) is a proximal signaling molecule of phosphatidylinositol-3-kinase, which is required for
metabolic activation [6]. Many other kinases, in addition to AKT, are known to be targets of PDK1 and
have attracted great interest in the scientific community. Among them are glucocorticoid-dependent
kinase (SGK), p70 ribosomal S6 protein kinase (S6K), p90 ribosomal protein S6 kinase (RSK),
and atypical PKC isoforms [6]. Du and coworkers revealed that mammary-specific ablation of PDK1
could delay tumor initiation, progression, and metastasis in a spontaneous mouse tumor model [7].
They also demonstrated that inducible deletion of PDK1 could noticeably shrink the growing breast
tumors. All of these results were obtained without AKT involvement [7].
In our laboratory, we developed a model to study different stages of melanoma progression.
Murine melanocytes were subjected to sequential cycles of substrate adhesion impediment,
thereby obtaining different cell lines representing pre-malignant melanocytes, non-metastatic
melanoma, and metastatic melanoma [8]. These cell lines show differences in the expression of
a variety of genes and proteins, including Timp1 [9]. Timp1 is a member of the family of matrix
metalloproteinase inhibitors, which contains four members (Timp1, Timp2, Timp3, and Timp4) [10].
Tissue inhibitors of metalloproteinases (TIMPs) are multifaceted molecules that exhibit properties
beyond their classical proteinase inhibitory function. In our model, we demonstrated a progressive
increase in Timp1 expression along the melanoma progression [9]. It was demonstrated that Timp1
confers higher survival, since melanocytes overexpressing Timp1 become able to resist anoikis and
form colonies in soft agar [9]. Moreover, melanoma cells overexpressing Timp1 acquire increased
capacity to metastasize in vivo [9]. In addition, we reported, for the first time, the assembly of a
supramolecular complex containing Timp1, CD63, and β1-integrins at the cell surface in melanoma
cells, and its involvement in the acquisition of an anoikis-resistant phenotype through the PI3K signaling
pathway [11]. However, the signaling pathway induced by Timp1 to protect melanoma cells from
apoptosis is still unknown. In the present study, we have investigated the mechanisms underlying
Timp1 role in melanoma progression. We present evidence that Timp1 overexpression increases
PDK1 phosphorylation at serine 241 and PKCβII at serine 660, and this increase results in an anoikis
resistance phenotype. We also observed that the simultaneous deletion of Timp1 and AKT prevents
more efficiently cell survival, providing a possible new therapeutic strategy for metastatic melanoma.
2. Results
2.1. Timp1 Silencing Results in Decreased Cell Survival in Vitro along with Melanoma Progression
Previous data from our laboratory showed increased Timp1 expression along melanoma
progression and more important the assembly of a supramolecular complex containing Timp1,
CD63, and β1-integrins associated with a more aggressive phenotype [9,11]. To further analyze
the role of Timp1 along the progression of melanoma, shRNA technology was used for silencing
Timp1 in cell lines representing different stages of melanoma progression: pre-malignant melanocytes
(4C), non-metastatic melanoma cells (4C11−), and metastatic melanoma cells (4C11+) (Figure 1A,B).
As previously demonstrated, Timp1 overexpression confers an anoikis-resistant phenotype to both
the murine melan-a melanocyte lineage and melanoma cell lines [9,11]. To further elucidate the
performance of Timp1 in providing greater capacity for survival, we conducted the analysis of
anoikis resistance in 4C, 4C11−, and 4C11+ cell lines silenced for Timp1. Only the melanoma
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cell lines 4C11− and 4C11+ were sensitized to cell death via anoikis in the absence of Timp1,
as shown by MTT assay (Figure 1C) and caspase-3 cleavage (Figure 1D) after adhesion impediment.
Regarding colony formation capacity (clonogenicity), a decrease was noted in all cell lines examined,
strengthening the role of Timp1 in cell survival in vitro (Figure 1E,F). In addition, the relevance
of Timp1 in apoptosis induced by others factors was evaluated by treating melanoma cells with
dacarbazine, a chemotherapeutic drug used in metastatic melanomas [12]. The half-maximal
inhibitory concentration (IC50) of dacarbazine was determined in melanoma cells silenced for Timp1.
In our model, increased sensitivity to dacarbazine was observed in melanoma cells silenced for
Timp1 (Figure 1G).
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period, the clone formation was, respectively, quantified and visualized after toluidine blue staining; 
and (G) the non-metastatic 4C11− and metastatic melanoma cell line 4C11+ were treated for 48 h with 
dacarbazine (IC50). After this period, cell viability was analyzed by MTT assay. ma: melan-a 
melanocytes; 4C: pre-malignant melanocytes; 4C11−: non-metastatic melanoma cell line; 4C11+: 
metastatic melanoma cell line; NT: control non-target shRNA; shTimp1#2: clone 2 silenced for 
Timp1; shTimp1#3: clone 3 silenced for Timp1. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. 
2.2. Timp1 Silencing Reverses the Aggressive Phenotype of Metastatic Melanoma Cells in Vivo 
Since the silencing of Timp1 conferred sensitivity to anoikis and reduced the colony formation 
along melanoma progression, we analyzed whether reducing Timp1 levels would affect tumor growth 
and lung colony formation in vivo. For this purpose, we injected metastatic melanoma 4C11+ cell line, 
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Figure 1. Downregulation of Timp1 decreases cell survival in melanoma cells. (A,B) Timp1
mRNA expression was assessed by RT-qPCR and Western blotting, respectively, in different cell
lines representing different stages of melanoma progression after transduction with viral particles
containing two different shRNA sequences for Timp1 (shTimp1#2 and shTimp1#3) or control non-target
shRNA (non-target, NT); (C,D) cell lines were maintained in suspension for 96 h and the number
of viable cells was estimated, respectively, using MTT and analysis of cleaved caspase-3 by Western
blotting; (E,F) 200 cells were incubated at 37 ◦C on 60 mm2 plates for 10 days. After this period,
the clone formation was, respectively, quantified and visualized after toluidine blue staining;
and (G) the non-metastatic 4C11− and metastatic melanoma cell line 4C11+ were treated for 48 h
with dacarbazine (IC50). After this period, cell viability was analyzed by MTT assay. ma: melan-a
melanocytes; 4C: pre-malignant melanocytes; 4C11−: non-metastatic melanoma cell line; 4C11+:
metastatic melanoma cell line; NT: control non-target shRNA; shTimp1#2: clone 2 silenced for Timp1;
shTimp1#3: clone 3 silenced for Timp1. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
2.2. Timp1 Silencing Reverses the Aggressive Phenotype of Metastatic Melanoma Cells In Vivo
Since the silencing of Timp1 conferred sensitivity to anoikis and reduced the colony formation
along melanoma progression, we analyzed whether reducing Timp1 levels would affect tumor growth
Cancers 2017, 9, 37 4 of 15
and lung colony formation in vivo. For this purpose, we injected metastatic melanoma 4C11+ cell
line, wild-type and silenced for Timp1, in the subcutaneous tissue of female C57BL/6 mice and
observed tumor growth. The 4C11+ cell line is extremely aggressive and, after 12 days, we noted tumor
growth in animals inoculated with control cells, but not with Timp1 silenced cells. Despite the expected
variability found in in vivo experiments, animals inoculated with both Timp1 silenced clones presented
a lag time of 14 days for the appearance of tumor mass (Figure 2A). On day 18, tumor weight was
measured and animals were sacrificed (Figure 2B). We observed a significant reduction in both the
volume and weight of tumors from animals inoculated with the cell lines silenced for Timp1.
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2.3. AKT Contributes to Anoikis Resistance in Metastatic Melanoma Cell Line Independently of Timp1 
Since AKT is a major downstream effector of PI3K in various cell types [2] and an important 
regulator of cell survival, we analyzed AKT activation along the melanoma progression. For this, we 
verified the activation pattern of AKT at threonine 308 (AKTThr308) by Western blot assay. We can see 
that only metastatic melanoma cell line 4C11+ has activated AKT (Figure 3A). To demonstrate the 
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Figure 2. Timp1 down-expression decreases in vivo tumor growth and lung colonization. Metastatic
melanoma cells 4C11+ (2 × 105) were injected subcutaneously into C57BL/6 mice (groups of five
animals) and the tumor volume (A) and weight (B) were determined; and (C,D) for experimental
metastasis assay, 2.5 × 105 cells were injected in the lateral tail vein of C57BL/6 mice. Mice were
sacrificed 21 days after injection, their lungs were removed, and the number of metastatic colonies in
the lung was determined. WT: wild-type 4C11+ metastatic melanoma cell line; non-target (NT): control
non-target shRNA; shTimp1#2: clone 2 silenced for Timp1; shTimp1#3: clone 3 silenced for Timp1.
Representative graphics of two independent experiments yielding similar results are shown. * p < 0.05,
** p < 0.01.
Our laboratory has shown that the increase in Timp1 expression provides greater efficiency in
metastases development, indicating a correlation between levels of Timp1 and a worse prognosis for
melanoma [9,11]. Moreover, various studies have correlated Timp1 increased expression in malignant
progression and poor prognosis, both in humans and in experimental tumor models. We observed
the effect of silencing Timp1 in the development of lung colonies after injecting 4C11+ intravenously.
Cells were inoculated via the lateral tail of female C57BL/6 mice and, after 21 days, the lungs were
analyzed for the presence of colonies (Figure 2C,D). We observed that animals inoculated with silenced
Timp1 clones exhibited less lung metastatic nodules.
2.3. AKT Contributes to Anoikis Resistance in Metastatic Melanoma Cell Line Independently of Timp1
Since AKT is a major downstream effector of PI3K in various cell types [2] and an important
regulator of cell survival, e analyzed T activation along the melanoma progression. For this,
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we verified the activation pattern of AKT at threonine 308 (AKTThr308) by Western blot assay. We can
see that only metastatic melanoma cell line 4C11+ has activated AKT (Figure 3A). To demonstrate the
real impact of AKT in the metastatic 4C11+ cell line, we inhibited AKT through RNA interference
technology (Figure 3B) and checked if any change would occur in the anoikis sensitivity. In Figure 3C,
we found that the reduction of AKT rendered cells less able to resist to anoikis. As AKT is activated only
in the metastatic melanoma 4C11+ cell line (Figure 3A) and this activation was shown to contribute
to anoikis resistance (Figure 3C), we checked whether there would be a correlation between AKT and
Timp1. For this, we analyzed AKT activation in the Timp1 silenced cell lines. As shown in Figure 3D,
there is no change in AKT activation in melanoma cell lines silenced for Timp1.
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blotting. As loading control, total AKT and β-actin were used. (B) AKT activation was analyzed by
Western blotting in the 4C11+ cell line, treated with a non-target siRNA (siNT) and a siRNA specific
to AKT (siAKT). Total AKT and β-actin were used as loading controls. (C) Anoikis resistance was
d termin d after maintaining control (siNT) and siAKT 4C11+ cells in suspension for 96 h. (D) AKT
activation was nalyzed by Western blotting in 4C, 4C11−, and 4C11+ cell lines and their Timp1
sil nced clones. Total AKT and β- ctin (Actin) were used as loading control . WT: on-treated cells;
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2.4. P K1 Is Activated by Ti p1 along elano a Progression and Contributes to Cell Survival
e found that Ti p1 is highly expressed fro the pre- alignant 4C cell line to etastatic cell
line 4C11+ and that this high expression leads to increased anoikis resistance and clonogenic capacity.
e also observed that higher levels of Timp1 do not alter the AKT activation in metastatic cells,
thus showing no correlation between the increase in Timp1 and AKT phosphorylation. To elucidate
hich olecule(s) in the PI3 path ay is odulated by Ti p1, e analyzed P 1, a olecule
activated after being recruited to PIP3, in the cell lines silenced for Timp1. Recently, several studies have
investigated the role of PDK1 in tumors and there is evidence that PDK1 can activate other molecules
involved in cell survival, senescence, and proliferation independent of its AKT phosphorylating
activity [13–15]. We observed a decreased PDK1 activation in pre-malignant 4C cell line and in
melanoma cell lines 4C11− and 4C11+ silenced for Timp1 (Figure 4A).
ne of the ain roles of Ti p1 in our elano a progression odel is to confer anoikis resistance.
The above data indicate that Timp1 is related to the PDK1 activation, which could be related to anoikis
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resistance. To confirm this hypothesis, we submitted cell lines to the treatment with a PDK1 inhibitor,
GSK2334470 (Figure 4B), and evaluated the anoikis survival rate (Figure 4D) and the ability to form
colonies (Figure 4E,F). Figure 4B also confirms that PDK1 is a downstream target of PI3K in this model.
The efficiency of the PI3K inhibitor, LY294002, in abrogating AKT activation is shown in Figure 4C.
These data show that Timp1 confers cell survival by activating PDK1 along melanoma progression
and that in metastatic cells AKT activation also contributes to anoikis resistance (Figure 4G).Cancers 2017, 9, 37  6 of 15 
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Figure 4. PDK1 is activated by Timp1, along with melanoma progression, and contributes to
cell survival. (A) PDK1 activation was examined in cell lines 4C, 4C11−, and 4C11+ and their
Timp1-silenced clones. Total PDK1 and β-actin were used as loading controls. WT: non-treated
cells; non-target: control non-target shRNA; shTimp1#2: clone 2 silenced for Timp1; shTimp1#3:
clone 3 silenced for Timp1; (B) cell lines treated with LY294002 (PI3K inhibitor), GSK2334470 (PDK1
inhibitor), and Bisindolyl alei ide I (PKC inhibitor) were analyzed for PDK1 activation by estern
blotting. Total PDK1, β-actin (Actin), and GAPDH were used as loading controls; (C) 4C11+ metastatic
elanoma cells treated or not with LY294002 (PI3K inhibitor) were analyzed for AKT activation by
Western blotting. β-actin was used as a loading control; (D) cell lines non-treated (NT) or treated with
GSK2334470 (PDK1 inhibitor) were evaluated for anoikis resistance after maintained in suspension
for 96 h; (E,F) colony formation capacity was determined in cell lines non-treated (NT) or treated
with GSK2334470 (PDK1 inhibitor); and (G) cell lines corresponding to both early (4C and 4C11−)
and late (4C11+) stages of m lano a pr gressi n confer cell survival via Timp1 by activating PDK1
pathway. In metastatic cell line (4C11+), AKT also contributes to anoikis resistance. * p < 0.05, ** . 1,
*** 0.001.
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2.5. Timp1 Modulates the PKC Activation via PDK1 in the Early Stages of Melanoma
PDK1 is known to activate AKT at threonine 308, but it can also activate other molecules, such as
PKC and SGK [15]. In this way, we analyzed PKC activation along melanoma progression. Interestingly,
PKC was found to be activated in the early stages of melanoma, but not in metastatic cells (Figure 5A).
To confirm that PKC is a downstream molecule of Timp1, we analyzed PKC activation in the cell
lines silenced for Timp1. The cell lines presenting activated PKC (pre-malignant melanocytes 4C and
non-metastatic melanoma cells 4C11−), but not metastatic cells, had reduced PKC activation when
Timp1 was silenced (Figure 5B).
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activation was analyzed by Western blotting in the melan-a (ma), 4C, 4C11−, and 4C11+ cell lines.
Total PKC and β-actin (Actin) were used as loading controls. (B) PKC activation was analyzed by
Western blotting in cell lines silenced for Timp1. Total PKC and β-actin (Actin) were used as loading
controls. WT: non-treated cell lines; non-target: control non-target shRNA; shTimp1#2: clone 2 silenced
for Timp1; and shTimp1#3: clone 3 silenced for Timp1. (C) PKC activation was determined in cell lines
(4C and 4C11−) treated with LY294002 (PI3K inhibitor) or GSK2334470 (PDK1 inhibitor). The control
was subjected to the same conditions without any treatment (non-treated). Total PKC andβ-actin (Actin)
were used as loading controls. (D) Anoikis resistance was analyzed in pre-malignant 4C melanocytes
and non-metastatic elanoma 4C11- cell lines, non-treated and treated with Bisindolylmaleimide I
(PKC inhibitor). (E,F) Colony formation was evaluated in 4C and 4C11- cell lines, non-treated and
treated with Bisindolylmaleimide I (PKC inhibitor). (G) Cell survival is favored by Timp1 in early
stages of melanoma progression by activation of the PDK1/PKC pathway. In late stages (metastasis),
both PDK1 activated by Ti p1 and AKT independently of Timp1 contribute to cell survival. melan-a:
melanocytes; 4C: pre-malignant melanocytes; 4C11−: non-metastatic melano a cell line; 4 11+:
metastatic melanoma cell lin ; * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
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To confirm that PKC is a downstream target of PI3K and PDK1, we treated cell lines with specific
inhibitors for PI3K and PDK1 (Figure 5C). As it was shown that the PKC is activated only in cell lines
4C and 4C11−, and that this activation is reversed in cell lines silenced for Timp1, the next step was
to define the PKC role in cell survival. The cell lines were treated with a specific inhibitor of PKC,
Bisindolylmaleimide I, and the number of cells surviving to anoikis and the ability to form colonies were
analyzed. Pharmacological inhibition of PKC was able to reduce both the anoikis resistance (Figure 5D)
and colony formation (Figure 5E,F). These data indicate that the role of the PI3K/PDK1/PKC pathway
in cell survival induced by Timp1 in the early stages of melanoma progression, whereas in metastatic
cells, both PDK1 induced by Timp1 and AKT, contribute to cell survival (Figure 5G).
2.6. Simultaneous Inhibition of Timp1 and AKT Impairs More Efficiently the Survival of Metastatic
Melanoma Cells
Our results demonstrated that decreasing Timp1 results in a less efficient anoikis resistance, colony
formation and resistance to the drug dacarbazine in vitro (Figure 1). In vivo, Timp1 reduction was able
to reduce dramatically tumor formation and the number of metastatic lung colonies (Figure 2). We also
showed that Timp1 modulates phosphorylation of PDK1 and PKC along melanoma progression
(Figures 4A and 5B). In addition, AKT appeared to play a key role in the anoikis resistance in metastatic
melanoma cells 4C11+ cells (Figure 3C). The next step was to determine whether the simultaneous
inhibition of AKT and Timp1 would have a stronger effect on anoikis resistance in metastatic cells,
since phosphorylated AKT is only found in these cells. For this purpose, we silenced AKT in 4C11+
metastatic cell line previously silenced for Timp1 and evaluated the anoikis resistance and caspase-3
cleavage. The simultaneous inhibition of Timp1 and AKT resulted in anoikis inhibition (Figure 6A) and
increased caspase-3 cleavage (Figure 6B) in a more effective way.
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resistance and malignant potential [9,11]. We also demonstrated that Timp1 associates differentially
with CD63 and β1-integrins along melanoma progression and that this association may be related
to the induction of the PI3K signaling pathway [11]. Moreover, we have shown that, in human
metastatic melanoma cells, Timp1 and CD63 expression are increased and positively correlated with
colony formation capability [11], strengthening the possible role of Timp1 in human melanoma genesis.
Here we provide evidence for the mechanisms by which Timp1 contributes to melanoma progression
through increasing cell survival.
We determined signaling pathways activated by Timp1 in cell lines corresponding to different
phases of melanoma progression, performing a genetic approach using transfection assays to inhibit
Timp1 gene expression. Decreasing Timp1 expression in 4C11− and 4C11+ melanoma cells resulted
in less effective anoikis resistance, colony formation, chemotherapy resistance, in vivo tumor growth,
and metastatic colony formation in the lung (Figures 1 and 2), showing that Timp1 confers advantages
which are essential for melanoma development, as it was shown for some other cancers. In epithelial
breast cancer cells, TIMP1 induced TWIST1 expression, leading to E-cadherin downregulation and
epithelial mesenchymal transition in a CD63-dependent manner [16]. A recent study showed that in
hepatocellular carcinoma cells TIMP1 expression is associated with advanced TNM stage (classification
of malignant tumors), intrahepatic metastasis, portal vein invasion, and vasculature invasion [17].
Bjerre et al. demonstrated that low expression of TIMP1 displayed significantly reduced sensitivity to
the anti-estrogen fulvestrant and gene expression analysis revealed association between expression
of TIMP1 and genes involved in metabolic pathways, epidermal growth factor receptor 1/cancer
signaling pathways, and cell cycle [18]. In fact, different authors have confirmed a positive correlation
of high TIMP1 expression with a poor prognosis in lung, brain, prostate, breast, colon, and several
other cancers [19,20].
Aberrant PI3K/AKT signaling has been studied extensively in cancer and the relationship between
the PI3K/AKT signaling pathway and tumor is clear. Dysregulation of the PI3K transduction pathway
is associated with more than 50% of melanomas, contributing to malignant transformation and tumor
progression by different mechanisms. We observed previously that Timp1 contributes to melanoma
development activating PI3K signaling pathway since wortmaninn and LY inhibit anoikis resistance,
a hallmark of cancer, acquired by melanocytes overexpressing Timp1 [11]. AKT, the main effector of
the PI3K signaling pathway, was found to be activated in the 4C11+ metastatic melanoma cell line
(Figure 3A) contributing to cell survival (Figure 3C). In human colon cancer cells, it was shown that
TIMP1 positively regulates proliferation and renders tumor cells more resistant to apoptosis through
the activation of FAK-PI3K/AKT and the MAPK signaling pathway [21]. Moreover, in human breast
cancer cells, RNAi-mediated silencing of TIMP1 induced cell cycle arrest at the G1 phase associated
with AKT and NFκB signaling pathway inhibition [20]. However, in our model, Timp1 is not involved
in AKT activation since decreased Timp1 expression did not affect AKT phosphorylation in melanoma
cells (Figure 3D). In the same way, AKT activation in melanocytes submitted to anchorage blockade was
not affected by Timp1 overexpression [11]. Canonically, AKT is activated following growth and survival
factors by a dual phosphorylation mechanism dependent on PI3K. However, it was recently shown
that phosphoinositide 3-kinase-related kinases (PIKKs), including mammalian targets of rapamycin
complex 2 (mTORC2), DNA-dependent protein kinase (DNA-PK), and ataxia telangiectasia mutated
(ATM), are implicated in AKT regulation as a result of sustained stress conditions, including DNA
damage and nutrient starvation [22–24]. Induction of DNA strand breaks recruits and activates
DNA-PK to sites of DNA damage, which, in turn, stimulates AKT phosphorylation, promoting cell
survival by induction of p21, a pro-survival transcription factor [23]. In fact, in our model p21 was
shown to be phosphorylated by AKT and retained to the cytoplasm, where it plays a role in drug
resistance [25]. The mechanisms associated with AKT activation independently of PI3K stimulation by
TIMP1 in melanoma cells are under investigation.
It was also shown that the PI3K signaling pathway can act independent of AKT in tumorigenesis
since PIK3CA mutant tumors have strikingly low levels of phosphorylated and activated AKT [26].
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In human breast cancer cells, PI3K promotes anchorage-independent growth and colony formation
in soft agar even in minimal AKT activation [27]. Activation of downstream targets via PI3K
signaling is defined by substrate conformation and subcellular localization. A moderate amount
of PDK1 at the membrane is sufficient to activate substrates in a PI3K-dependent manner, unlike
AKT, which requires simultaneous protein-protein interactions following 3′-phosphatidylinositol
synthesis. Following growth factor stimulation, PI3K is activated and PDK1 is found at the plasma
membrane, where it binds to the phosphatidylinositol 3,4,5-trisphosphate [PtdIns(3,4,5)P3] second
messenger which, in turn, can activate a group of kinases belonging to the AGC protein family, such
as PKA, PKG, PKC, and GSK3 [28,29]. PDK1 expression, activation, and subsequent stimulation of
downstream substrates can also be regulated by c-Jun transcription factor contributing to melanoma
growth [30]. These enzymes regulate important processes of carcinogenesis, such as protein synthesis,
metabolism, survival, and proliferation. PDK1 contributes to development of melanoma harboring
the wild-type or knockout Pten genotype [14,31]. These authors also showed that inhibition of PI3K
signaling effectively synergize with the PDK1 inhibitor, showing a novel therapeutic approach in
melanoma treatment [14,31]. Interestingly, in our melanoma progression model, Timp1 was shown
to modulate the PI3K/PDK1 axis, since decreased Timp1 expression and PI3K inhibition attenuated
PKD1 phosphorylation along with melanoma genesis (Figure 4A). PDK1 contributes to cell survival
since its pharmacological inhibition dramatically increased anoikis sensitivity and decreased colony
formation (Figure 4D–F). These observations corroborate the data showing that PDK1 inhibitors might
have therapeutic utility for cancer treatment. Recent studies also suggest that PDK1 inhibitors may
have other benefits, including reduction of cancer cell resistance to chemotherapeutic drugs, such as
Tamoxifen [32,33].
The PKC isoforms are activated by multiple mechanisms, including PI3K/PDK and MAPK
kinases ERK and JNK after receptor tyrosine kinase and G protein coupled receptor stimulation
in a variety of cells regulating innumerous biological process. Cell-specific functions performed
by PKC enzymes are determined by a combination of different factors, including PKC isoform
profiles, substrate specificity, subcellular localization, and protein interactions [34]. PKCα/β II
and PCKδ, but not PKCξ, are phosphorylated in response to VEGF-mediated PI3K activation and
contribute to vasculogenesis [35]. PKC activation is also associated with the regulation of both
innate and adaptive immunity, being activated by Toll-like receptors, B-cell, and T-cell receptors [36].
In melanoma cells, PKC signaling pathway activation was found to be involved in both oncogenic
or tumor suppressive effects [34]. Concomitant inhibition of PKC and p53-MDM2 or PKC and
mTORC1 pathways efficiently decreased cell survival and increased apoptosis of uveal melanoma
cells, providing a very attractive treatment [37]. However, overexpression of the PCKδ isoform in
B16F10 melanoma cells resulted in suppressed ceramide production and induced cell death [38]. In our
model we detected increased levels of phosphorylated PKC isoforms α, β, βII, δ, ε, η, and θ only in
pre-malignant 4C cells and non-metastatic 4C11− cells (Figure 5A), which correspond to early stages
of melanoma development. Activation of PKC is downstream a PI3K/PDK signal transduction, since
PKC phosphorylation was abrogated in the presence of PI3K and PDK inhibitors (Figure 5C). It was
shown that the PKC signaling pathway regulates TIMP1 expression in connective tissue following
myocardium injury and inflammation, contributing to tissue remodeling [38]. In addition, increased
PCK activity induced by phorbol-12-myristate-13-acetate (PMA) augments TIMP1 expression in colon
cancer cells [39]. However, the regulation of PKC signal transduction by TIMP1 was not observed.
Here, we demonstrated that PKC activation in early phases of melanoma genesis requires TIMP1
(Figure 5B) and it is critical to favor cell survival (Figure 5D–F). Activation of other signaling pathways
that contribute to melanoma development and are downstream of the PI3K/PDK axis, including
glucocorticoid-induced protein kinase (SGK) isoforms, glycogen synthase kinase 3 (GSK3), and Jun
N-terminal kinase (JNK), cannot be excluded and are under investigation.
As previously discussed, AKT is also important and was shown to be acting independently of
Timp1 in the metastatic melanoma 4C11+ cell line. In Figure 3C, we note that AKT is extremely
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important for the aggressive status of this cell line, since transient AKT reduction has led to a decreased
anoikis resistance. However, the decrease of AKT in cell lines silenced for Timp1 led to a more effective
reduction of anoikis resistance, showing that Timp1 and AKT have synergistic effects to promote cell
survival (Figure 6). Taken together, this finding indicates that simultaneous inhibition of Timp1 and
AKT might be a potential strategy in the fight against metastatic melanoma.
4. Materials and Methods
Cell culture: Non-tumorigenic melan-a melanocyte lineage was cultured at 37 ◦C in humidified
95% air-5% CO2 in RPMI pH 6.9 supplemented with 5% fetal bovine serum (Invitrogen, Carlsbad,
CA, USA), 200 nM 12-phorbol-13-myristate acetate (PMA; Calbiochem, Darmstadt, Germany),
100 U/mL penicillin, and 100 U/mL streptomycin (Invitrogen) [40]. A murine melanocyte malignant
transformation model was developed in our laboratory using melan-a melanocyte lineage [8].
Briefly, cell lines were established after melan-a melanocytes were submitted to 1–4 cycles of
substrate impairment adhesion (namely 1C, 2C, 3C, and 4C cell lines, respectively), giving rise
to cell lines representing pre-malignant cells. Pre-malignant 4C melanocytes were subjected to a
new cycle of anchorage blockade and the spheroids formed were submitted to a limiting dilution,
giving rise different melanoma cells lines (e.g., non-metastatic 4C11− and metastatic 4C11+ cell
lines) [8]. Pre-malignant 4C melanocyte lineage and their clones (non-target, shTimp1#2, shTimp1#3),
non-metastatic 4C11− and their clones (non-target, shTimp1#2, shTimp1#3), and metastatic 4C11+
melanoma cell lines and their clones (non-target, shTimp1#2, shTimp1#3) were cultured as melan-a
cells, but in the absence of PMA.
Reagents: All reagents were diluted in DMSO at the following concentrations: 1 µM LY294002
(PI3K inhibitor), 1 µM GSK2334470 (PDK1 inhibitor) and 2 µM Bisindolylmaleimide I (PKC inhibitor).
All reagents were purchased from Sigma-Aldrich (Sigma-Aldrich Inc., St. Louis, MO, USA).
Stable silencing of Timp1 by shRNA: Timp1 was silenced by shRNA—MISSION® shRNA Plasmid
DNA (pLKO.1-puro) from Sigma-Aldrich. Two plasmids carrying different shRNA sequences for
Timp1 (shTimp1#2, clone ID: NM_011593.1-167s1c1, and shTimp1#3, clone ID:NM_011593.1-470s1c1)
and a control plasmid containing a non-target sequence (non-mammalian shRNA control, TCR1,
SHC002). These sequences were previously validated for the target. Lentiviral particles were produced
by the calcium phosphate precipitation method in 293T cells, co-transfecting the lentiviral plasmids
containing the shRNA sequences, with packaging plasmids. Viral supernatants were aliquoted and
stored at −80 ◦C. Lentiviral titers were determined by limiting dilution and puromycin selection in
HT1080 cells (ATCC, Manassas, VA, USA) and quantified as the number of transducing units (TU)
per milliliter. These lentiviral particles were used to establish cell lines with knockdown of Timp1
or expressing the non-target shRNA sequence as a control. All transductions were performed using
a MOI (multiplicity of infection) of 0.5, in the presence of 8 µg/mL polybrene. After transduction
puromycin-resistant cells were selected. The target silencing was verified by RT-qPCR.
Transient silencing of AKT: Metastatic melanoma cell line 4C11+ was plated in six-well plates
(5 × 104 cells per well) and maintained in culture for 24 h. Nine microliters of Lipofectamine®
RNAiMAX Reagent (Life Technologies, Carlsbad, CA, USA) were diluted in 150 µL of Optim-MEM®
medium (Life Technologies). Thirty picomoles of siRNA (AmbionTM, Burlington, Ontario, Canada)
were diluted in 150 µL of Optim-MEM® medium (Life Technologies). Both solutions containing
Lipofectamine® RNAiMAX Reagent (Life Technologies) and siRNA (Silencer® Select AKT1 (AmbionTM,
cat. #4390771) were mixed and incubated for 5 min at room temperature. After 5 min, the solution
containing the siRNA was dripped into wells. The cell lines were maintained in culture for 48 h
and, after that time, cells were used for anoikis resistance assay. For the control, cells lines were
transfected with a non-targeting negative control siRNA (Silencer® Select Negative Control No. 1
siRNA, AmbionTM, cat. #4390843) as described above. The negative control has the same chemical
modifications as Silencer® Select siRNA but without targeting any RNA.
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Western blotting: Subconfluent cell cultures were trypsinized, washed with PBS and
membrane-enriched protein extracts were prepared using cold NP-40 lysis buffer (10% NP-40
in 100 mMNaCl and 50 mMTris pH 7.4, containing 30 mM sodium pyrophosphate, 50 mMNaF,
1 mM NaVO4, 2 µg/mL aprotinin, 2 µg/mL leupeptin, 2 µg/mL pepstatin, and 1 mM PMSF),
kept for 15 min on ice, followed by centrifuging at 10,000 rpm for 15 min at 4 ◦C. The supernatant
was collected and the protein concentration was measured by Bio-Rad protein assay dye
reagent concentrate (Bio-Rad, Hercules, CA, USA). Equivalent amounts of protein (50 µg) were
denaturated in SDS-sample buffer (240 mMTris-HCl pH 6.8, 0.8% SDS, 200 mMβ-mercaptoethanol,
40% glycerol, and 0.02% bromophenol blue) for 5 min, then separated by electrophoresis in
SDS-polyacrylamide gels and transferred to a polyvinylidenedifluoride membrane (Amersham,
Piscataway, NJ, USA). After protein transfer, the membranes were blocked with 5% non-fat dry milk
in PBS (10 mM phosphate buffer pH 7.2, 150 mMNaCl), incubated with the indicated antibodies:
anti-GAPDH (#ABS16, Chemicon, Darmstadt, Germany), anti-actin (A2103, Sigma-Aldrich),
anti-phospho-AKTThr308 (#9275, Cell Signaling Technology) and anti-AKT (#4691, Cell Signaling
Technology), anti-phospho-PDK1Ser241 (#3061, Cell Signaling Technology), anti-PDK1 (#3062, Cell
Signaling Technology), anti-phospho-PKC(pan)(βIISer660) (#9371, Cell Signaling Technology),
anti-PKC (sc-17769, Santa Cruz Biotechnology, Dallas, TX, USA), caspase-3 (CSB-PA05689A0Rb,
Flarebio Biotech LLC, College Park, MD, USA), and Timp1 (CSB-PA024013YA01HU, Flarebio Biotech
LLC) overnight at 4 ◦C and the signal was detected using horseradish peroxidase-conjugated
anti-immunoglobulin G antibody (KPL, Gaithersburg, MD, USA) followed by development using
chemiluminescence substrate (SuperSignal West Pico Chemiluminescent Substrate; Pierce Chemical,
Rockford, IL, USA).
MTT assay: To estimate cell proliferation, 2 × 103 cells were plated in 96-well plates, and cell
viability was determined by MTT assay every 24 h. To this, MTT (5 µg/mL final concentration)
(Calbiochem) was added to the culture. The cells were kept in an incubator (37 ◦C and 5% CO2) for
one hour. MTT was removed from the wells by inverting the plate and 100 µL of isopropanol were
added to each well (Merck, Darmstadt, Germany). After 15 min, the absorbance was measured with
a spectrophotometer (OD = 620 nm) (Multiskan EX/Thermo Electron Corp., Waltham, MA, USA).
The same procedure described above was carried out to determine viable cells both after treatment
with the drug and anoikis resistance assay.
Anoikis resistance assay: Cell lines 4C wild-type, 4C non-target (TRC2), 4C shTimp1#2, 4C
shTimp1#3, 4C11− wild-type, 4C11− non-target (TRC2), 4C11− shTimp1#2, 4C11− shTimp1#3, 4C11+
wild-type, 4C11+ non-target (TRC2), 4C11+ shTimp1#2, 4C11+ shTimp1#3, 4C11− non-target (AKTi
CTL), 4C11− AKTi, 4C11+ non-target (AKTi CTL), and 4C11+ AKTi (5 × 104) were maintained
for 96 h in 100 mm2 dishes coated with 1% agarose, with or without treatment with specific
inhibitors. After 96 h, cell viability was assessed by MTT and/or analyzed for caspase-3 cleavage by
Western blotting.
Colony formation assay (clonogenicity). Cell lines (106) were treated or not with the inhibitors.
After 24 h of treatment, cells were trypsinized and 200 cells were plated to visualize the formation of
colonies. After 10 days, the colonies were washed with PBS, fixed with 3.7% paraformaldehyde for
15 min, stained with 1% toluidine blue for 5 min and washed with water. For quantification of viable
cells, the cells were lysed and the dye solubilized in 1% SDS for 4 h and the absorbance at 620 nm was
measured using a plate reader.
Determination of IC50 dose: To determine the IC50 dose of the drug dacarbazine, melanoma cell
lines (2.5 × 103) were plated in 96-well plates. Twenty-four hours after cell adhesion, serial dilution of
the drug was accomplished in the following concentrations: 0, 200, 400, 600, 800, and 1000 µM in order
to determine the IC50. After 48 h, cell viability was assessed by MTT assay.
Tumor growth assay: Cells (2 × 105) were inoculated in the subcutaneous tissue of the dorsal
region of female C57BL/6 mice (five animals per group). After 12 days, tumor formation was observed
and measured every two days. On day 18, mice were sacrificed and the tumor weight determined.
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All procedures involving animals were performed after approval from the Research Ethics Committee
of the Universidade Federal de São Paulo, Brazil (Approval number: CEP 2116/11).
Lung colonization assay: Cells (2.5 × 105) were inoculated on the lateral tail vein of female
C57BL/6 mice. After 21 days, the animals were sacrificed and the presence of colonies in the lung
was analyzed.
Statistical analyses: All tests were conducted in biological triplicate. The results were organized
into a database using the statistical program GraphPad Prism 5 (GraphPad Software Inc., La Jolla, CA,
USA). The level of significance utilized was p < 0.05. The statistical tests performed were: Student’s
t-test for unpaired samples, and one-way ANOVA followed by Tukey’s multiple comparison tests.
5. Conclusions
Our data provides evidence that Timp1 confers cell survival by activating PDK1 signaling
pathway and that Timp1 and AKT have synergistic effects to confer anoikis resistance in metastatic
melanoma cells.
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